GlassScriptPhysician profile
Pornchai Jonglertham
NPI 1265567242
$48,388.62
in general payments reported to CMS, 2019-2025
50 companies · $12K in 2025
The $12K reported for 2025 was more than what 90% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $7,970 · 2020: $2,887 · 2021: $5,797 · 2022: $4,439 · 2023: $12K · 2024: $3,187 · 2025: $12K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $16K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $6,006 · Travel and Lodging: $2,808 · Food and Beverage: $2,688 · Education: $86.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $15,706.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $6,006.00 |
| Travel and Lodging | $2,808.49 |
| Food and Beverage | $2,688.03 |
| Education | $86.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $15,261.08 | 2019-2025 | Zynyz, Pemazyre, Jakafi |
| Astrazeneca Pharmaceuticals LP | $11,515.82 | 2019-2025 | Imfinzi, Calquence, Tagrisso |
| Jazz Pharmaceuticals INC. | $7,605.35 | 2020-2025 | |
| Beone Medicines USA, INC. | $4,208.00 | 2025 | Brukinsa |
| Karyopharm Therapeutics INC. | $2,262.01 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $1,417.45 | 2019-2023 | |
| Janssen Biotech, INC. | $1,128.70 | 2019 | |
| Aveo Pharmaceuticals, INC. | $1,000.00 | 2023 | Fotivda |
| Daiichi Sankyo INC. | $603.97 | 2020-2023 | Enhertu |
| E.R. Squibb & Sons, L.L.C. | $310.72 | 2019-2024 | Krazati |
| Astellas Pharma US INC | $277.06 | 2019-2025 | Vyloy |
| Seagen INC. | $266.96 | 2019-2023 | Adcetris |
| Genzyme Corporation | $239.43 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $162.04 | 2019-2023 | Iclusig |
| Abbvie INC. | $160.55 | 2024 |
Show all 47 companies
3 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pornchai Jonglertham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.